All In Biotech

NDA 010187 · Sandoz

Ritalin

Methylphenidate Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Feb 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1955

Dec 5, 1955

Approved uses

1

Original approval plus efficacy supplements

Registered trials

456

101 Phase 3, 37 recruiting

FAERS reports

24,249

14,895 serious, 1,137 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION Ritalin has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Ritalin, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing Ritalin, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout Ritalin treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ) and Drug Abuse and Dependence ( 9.2 )]. WARNING: ABUSE, MISUSE, AND...

What it is approved for

From the label in effect Feb 5, 2025.

Ritalin is indicated for the treatment of: • Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults • Narcolepsy Ritalin is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy ( 1 ).

Mechanism: Methylphenidate hydrochloride is a CNS stimulant. The mode of therapeutic action in ADHD and narcolepsy is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • RITALIN · METHYLPHENIDATE HYDROCHLORIDE 10MG · TABLET, ORAL · Prescription · TE AB
  • RITALIN · METHYLPHENIDATE HYDROCHLORIDE 20MG · TABLET, ORAL · Prescription · TE AB
  • RITALIN · METHYLPHENIDATE HYDROCHLORIDE 5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Methylphenidate" as an intervention, any sponsor and status, largest first.

All 456 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,492
  • fatigue1,726
  • nausea1,471
  • headache1,395
  • anxiety1,352
  • depression1,172
  • somnolence989
  • off label use951
  • insomnia937
  • feeling abnormal904
  • dizziness852
  • weight decreased795

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004400
2005420
2006407
2007386
2008401
2009443
2010512
2011572
2012699
2013647
2014797
20151,779
20163,218
20171,771
20181,815
20191,649
20201,277
2021961
20221,203
20231,385
20241,288
20251,263
2026955

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ritalin (Methylphenidate HCl)

2024 spending

$720K

Beneficiaries

1,179

5,652 claims

Per beneficiary

$611

$1.36 per unit

View as table
YearSpending
2020$950,661
2021$940,209
2022$914,489
2023$756,187
2024$720,435

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,080 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.